相关实验视频

Updated: Jun 5, 2025

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

斯诺RNAs:对抗瘤治疗的有希望的目标

Xiaoyun Hu^1,2,3, Wanlin Cui^1,2, Min Liu^1,2

¹Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China.

Journal of pharmaceutical analysis

|December 5, 2024

概括

小核RNAs (snoRNAs) 是关键的癌症标记物,参与瘤进展和药物耐药性. 本综述详细介绍了它们的新型监管机制,功能和作为治疗点的潜力.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
遗传学遗传学是一个

背景情况:

小核RNAs (snoRNAs) 越来越被认为是癌症中关键的分子标记物.
它们的作用扩展到瘤病理学和对治疗的耐药性.
传统的研究重点是2'-O-ribose甲基化和伪尿基化.

研究的目的:

审查新的调节机制和snoRNAs在瘤中的功能作用.
探索snoRNA宿主基因 (SNHGs) 与癌症中的snoRNA之间的相互作用.
讨论snoRNAs的临床影响和治疗潜力.

主要方法:

关于癌症中snoRNA调节和功能的最近研究的文献综述.
对snoRNA参与转录,后转录和后翻译过程的分析.
检查snoRNA宿主基因相互作用和临床相关性.

主要成果:

在经典功能之外,SnoRNAs表现出各种不同的调节机制.
斯诺RNA和SNHG在促进瘤进展方面具有协同作用.
斯诺RNAs作为瘤基因或瘤抑制剂起作用,影响抗药性.

结论:

斯诺RNAs代表了癌症临床诊断和预后的重要生物标志物.
准snoRNAs为癌症治疗提供了有前途的治疗策略.
对snoRNA路径的进一步研究可以解锁新的药物标.

关键词:

癌症癌症癌症癌症多种药物耐药性多种药物耐药性有针对性的治疗.瘤的免疫微环境斯诺RNA 斯诺RNA 是一种斯诺RNA是宿主基因中的一个.

更多相关视频

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...